©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 21, 2012; 18(35): 4944-4958
Published online Sep 21, 2012. doi: 10.3748/wjg.v18.i35.4944
Published online Sep 21, 2012. doi: 10.3748/wjg.v18.i35.4944
Table 2 Grade 3 or 4 toxicity of selected clinical trials
| Ref. | Intervention | Vomiting | Diarrhea | Neutropenia | Anemia | Thrombocytopenia |
| Louvet et al[15] | Gem | 3.2 | 1.3 | 27.6 | 10.3 | 3.2 |
| Gem + Oxaliplatin | 8.9 | 5.7 | 20.4 | 6.4 | 14.0 | |
| Poplin et al[16] | Gem | 7 | 4 | 33 | 10 | 13 |
| Gem + Oxaliplatin | 16 | 6 | 22 | 6 | 11 | |
| Heinemann et al[17] | Gem | 5.9 | 4.7 | NR | 10.6 | 10.6 |
| Gem + Cisplatin | 22.2 | 3.3 | NR | 13.3 | 4.4 | |
| Colucci et al[18] | Gem | 2 | 0 | 9 | 4 | 2 |
| Gem + Cisplatin | 2 | 4 | 18 | 6 | 2 | |
| Colucci et al[19] | Gem | < 1 | 1.5 | 13.7 | 1 | 18.9 |
| Gem + Cisplatin | 2.6 | < 1 | 24.7 | 4.8 | 15.3 | |
| Kulke et al[20] | Gem | 24.1 | NR | 82.8 | 20 | 43.1 |
| Gem + Cisplatin | 29 | NR | 74.2 | 25.8 | 79 | |
| Gem + Irinotecan | 16.7 | NR | 41.7 | 8.3 | 23.3 | |
| Berlin et al[21] | Gem | 8 | NR | 5 | 10 | 11 |
| Gem + 5-fluorouracil | 7 | NR | 7 | 10 | 19 | |
| Herrmann et al[22,24] | Gem | 4 | 2 | 19 | 6 | 8 |
| Gem + Capeitabine | 4 | 5 | 23 | 8 | 4 | |
| Cunningham et al[23] | Gem | 6 | 4 | 22 | 6 | 6 |
| Gem + Capeitabine | 6 | 5 | 35 | 4 | 11 | |
| Scheithauer et al[25] | Gem | 0 | 0 | 7.6 | 0 | 2.5 |
| Gem + Capeitabine | 0 | 5 | 10 | 5 | 0 | |
| Costanzo et al[26] | Gem | 0 | 0 | 2 | 6 | 0 |
| Gem + 5-fluorouracil | 2 | 0 | 2 | 7 | 2 | |
| Abou-Alfa et al[27] | Gem | 3.1 | < 1 | 14.6 | 7.6 | 4.4 |
| Gem + Exatecan | 5.3 | 1.1 | 30.3 | 5.9 | 15.4 | |
| Stathopoulos et al[28] | Gem | 1.4 | 2.8 | 15.7 | 4.2 | 0 |
| Gem + Irinotecan | 1.6 | 3.2 | 26.6 | 5 | 5 | |
| Lima et al[29] | Gem | 8.2 | 1.8 | 31.9 | 13 | 14.2 |
| Gem + Irinotecan | 13.9 | 18.5 | 37.6 | 16.2 | 19.6 | |
| Moore et al[38] | Gem | NR | < 1 | 27% | NR | 11% |
| Gem + Erlotinib | NR | 2 | 24% | NR | 10% | |
| Cutsem et al[39] | Gem | 9 | 3 | 30 | 16 | 12 |
| Gem + Tipifarnib | 7 | 4 | 40 | 20 | 15 | |
| Eckhardt et al[40] | Gem | 9.3 | 0 | 33.9 | 11 | 15.3 |
| Gem + Tipifarnib | 4 | 0 | 35.5 | 12.1 | 16.1 | |
| Philip et al[37] | Gem | 2.2 | 2.5 | 23.9 | 6.2 | 8.5 |
| Gem + cetuximab | 6.6 | 2.8 | 23.3 | 9.7 | 6.6 | |
| Kindler et al[36] | Gem | NR | NR | 29 | 8 | 12 |
| Gem + Bevacizumab | NR | NR | 33 | 5 | 12 | |
| Kindler et al[35] | Gem | 3.2 | 1.6 | < 1 | < 1 | < 1 |
| Gem + Axitinib | 3.9 | 1.3 | 0 | 0 | 0 | |
| Spano et al[41] | Gem | 10 | 0 | 33 | 17 | 13 |
| Gem + Axitinib | 6 | 6 | 28 | 8 | 20 | |
| Richards et al[33] | Gem | 0 | 2.6 | 28.2 | 5.1 | 25.6 |
| Gem + Enzastarin | 2.4 | 3.7 | 18.3 | 3.7 | 14.6 | |
| Bramhall et al[31] | Gem | 14% | NR | NR | 7% | NR |
| Gem + Marimastat | 6% | NR | NR | 3% | NR | |
| Richards et al[32] | Gem | 9 | 3 | NR | 5 | 11 |
| Gem + CA-994 | 9 | 5 | NR | 13 | 2 | |
| Oettle et al[30] | Gem | 3.7 | 0.7 | 12.8 | 2.9 | 6.2 |
| Gem + Pemetrexed | 3.3 | 2.9 | 45.1 | 13.9 | 17.9 |
- Citation: Sun C, Ansari D, Andersson R, Wu DQ. Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer? World J Gastroenterol 2012; 18(35): 4944-4958
- URL: https://www.wjgnet.com/1007-9327/full/v18/i35/4944.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i35.4944